Lifesci Capital Stock Recommendations and Price Targets

This is a list of recent ratings by Lifesci Capital.

Date	Company Name	Action	Current Price	Price Target	Rating	Impact on Share Price
10/22/2024	KURA Kura Oncology	Upgrade	$16.00		Strong-Buy	High
10/10/2024	OKUR OnKure Therapeutics	Upgrade	$17.00		Strong-Buy	High
10/3/2024	LQDA Liquidia	Initiated Coverage	$10.00	$30.00	Outperform	Low
10/2/2024	LQDA Liquidia	Upgrade	$10.00		Strong-Buy	High
9/16/2024	ORKA Oruka Therapeutics	Initiated Coverage	$24.00	$41.00	Outperform	Medium
9/9/2024	AURA Aura Biosciences	Upgrade	$9.00		Strong-Buy	Medium
8/26/2024	CELC Celcuity	Initiated Coverage	$13.00	$27.00	Outperform	Low
8/21/2024	CRBP Corbus Pharmaceuticals	Upgrade	$17.00		Strong-Buy	Low
7/31/2024	ALXO ALX Oncology	Downgrade	$1.00		Strong-Buy ➝ Hold	Low
7/29/2024	MRSN Mersana Therapeutics	Upgrade	$2.00		Strong-Buy	Low
7/29/2024	RPTX Repare Therapeutics	Upgrade	$3.00		Strong-Buy	Low
7/29/2024	IDYA IDEAYA Biosciences	Upgrade	$27.00		Strong-Buy	Low
7/29/2024	MRUS Merus	Upgrade	$47.00		Strong-Buy	Low
7/29/2024	NUVL Nuvalent	Upgrade	$87.00		Strong-Buy	Low
6/11/2024	DNTH Dianthus Therapeutics	Upgrade	$23.00		Strong-Buy	Low
5/28/2024	CALT Calliditas Therapeutics AB (publ)	Downgrade	$40.00		Strong-Buy ➝ Hold	Low
5/6/2024	CATX Perspective Therapeutics	Reiterated Rating	$8.00		Outperform	N/A
3/26/2024	MLYS Mineralys Therapeutics	Reiterated Rating	$11.00		Outperform	Low
2/28/2024	VTYX Ventyx Biosciences	Upgrade	$2.00		Market Perform ➝ Outperform	Low
2/27/2024	GPCR Structure Therapeutics	Reiterated Rating	$34.00		Outperform	Low
2/20/2024	LRMR Larimar Therapeutics	Reiterated Rating	$7.00		Outperform	Low
1/23/2024	INBX Inhibrx	Downgrade	$14.00		Outperform ➝ Market Perform	Low
1/5/2024	IVA Inventiva	Reiterated Rating	$3.00		Outperform	Low
12/26/2023	TARS Tarsus Pharmaceuticals	Reiterated Rating	$45.00		Outperform	Low
12/26/2023	RCKT Rocket Pharmaceuticals	Reiterated Rating	$14.00		Outperform	Low
12/4/2023	SYRE Spyre Therapeutics	Reiterated Rating	$29.00		Outperform	Low
11/27/2023	TCRX TScan Therapeutics	Reiterated Rating	$4.00		Outperform	Low
11/7/2023	VTYX Ventyx Biosciences	Downgrade	$2.00		Outperform ➝ Market Perform	Low
8/8/2023	TNYA Tenaya Therapeutics	Reiterated Rating	$2.00		Outperform	Low
8/8/2023	INBX Inhibrx	Reiterated Rating	$14.00		Outperform	Low
8/8/2023	VERV Verve Therapeutics	Reiterated Rating	$5.00		Outperform	Low
4/26/2023	PYXS Pyxis Oncology	Reiterated Rating	$4.00		Outperform	Low
4/26/2023	OLMA Olema Pharmaceuticals	Reiterated Rating	$9.00		Outperform	Low
4/26/2023	ALXO ALX Oncology	Reiterated Rating	$1.00		Outperform	Low
4/26/2023	AVDL Avadel Pharmaceuticals	Reiterated Rating	$11.00		Outperform	Low
4/26/2023	INBX Inhibrx	Reiterated Rating	$14.00		Outperform	Low
4/24/2023	IRON Disc Medicine	Reiterated Rating	$59.00		Outperform	Low
4/11/2023	AKRO Akero Therapeutics	Reiterated Rating	$28.00		Outperform	Low
4/5/2023	IFRX InflaRx	Upgrade	$2.00		Market Perform ➝ Outperform	Low
3/27/2023	CRNX Crinetics Pharmaceuticals	Reiterated Rating	$55.00		Outperform	Low
3/8/2023	OBIO Orchestra BioMed	Reiterated Rating	$6.00		Outperform	Low
3/7/2023	ELVN Enliven Therapeutics	Reiterated Rating	$24.00		Outperform	Low
12/21/2022	MLTX MoonLake Immunotherapeutics	Reiterated Rating	$49.00		Outperform	N/A
12/1/2022	PYXS Pyxis Oncology	Reiterated Rating	$4.00		Outperform	Low
11/28/2022	ATXS Astria Therapeutics	Reiterated Rating	$9.00		Outperform	Low
11/8/2022	ALXO ALX Oncology	Reiterated Rating	$1.00		Outperform	Low
8/12/2022	VYNE VYNE Therapeutics	Downgrade	$3.00		Outperform ➝ Market Perform	Low
8/12/2022	LRMR Larimar Therapeutics	Upgrade	$7.00		Market Perform ➝ Outperform	Low
6/16/2022	TNYA Tenaya Therapeutics	Reiterated Rating	$2.00		Outperform	Low
3/28/2022	VERA Vera Therapeutics	Reiterated Rating	$46.00		Outperform	Low
3/25/2022	ELDN Eledon Pharmaceuticals	Reiterated Rating	$4.00		Outperform	Medium
3/22/2022	LHDXQ Lucira Health	Upgrade	$0.00		Market Perform ➝ Outperform	Low
2/16/2022	LRMR Larimar Therapeutics	Downgrade	$7.00	$3.00	Outperform ➝ Market Perform	Medium
12/22/2021	ALLK Allakos	Downgrade	$1.00		Outperform ➝ Market Perform	High
12/22/2021	VERV Verve Therapeutics	Reiterated Rating	$5.00		Outperform	High